Related Experiment Video
Updated: Jun 11, 2026
23:33
The WATCHMAN Left Atrial Appendage Closure Device for Atrial Fibrillation
Published on: February 28, 2012
New antithrombotic agents--insights from clinical trials
Jeremy S Paikin1, John W Eikelboom, John A Cairns
1Department of Medicine, McMaster University, Hamilton General Hospital, 237 Barton Street East, Hamilton, Ontario, Canada. paikinjs@mcmaster.ca
Nature Reviews. Cardiology
|June 30, 2010
Summary
New antithrombotic agents offer improved efficacy and safety over traditional therapies for both arterial and venous thrombosis. This review examines novel antiplatelet drugs and new oral anticoagulants, explaining their clinical trial outcomes.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Hematology
Background:
- Antithrombotic agents are crucial for managing thrombosis, with distinct agents for arterial (antiplatelets) and venous (anticoagulants) clots.
- Existing treatments like acetylsalicylic acid and coumarins have limitations, including variable efficacy, drug interactions, and monitoring challenges.
- Newer antithrombotic agents have been developed to overcome these limitations.
Purpose of the Study:
- To review novel antiplatelet agents targeting the ADP-receptor.
- To review new oral anticoagulants designed for venous thromboembolism.
- To provide explanations for the outcomes observed in Phase III clinical trials of these new antithrombotic drugs.
Main Methods:
- Review of current literature on antithrombotic agents.
- Analysis of Phase III randomized controlled trial data for new antiplatelet drugs (prasugrel, ticagrelor, cangrelor).
- Analysis of Phase III randomized controlled trial data for new oral anticoagulants (dabigatran etexilate, rivaroxaban, apixaban).
Main Results:
- Newer ADP-receptor inhibitors show promise in addressing limitations of clopidogrel.
- New oral anticoagulants offer alternatives to coumarins with potentially improved safety and convenience.
- Phase III trials provide evidence for the efficacy and safety profiles of these novel agents.
Conclusions:
- Novel antithrombotic agents represent significant advancements in managing arterial and venous thrombosis.
- These new drugs offer improved therapeutic options compared to older agents.
- Understanding their mechanisms and trial results is key for clinical application.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:29Venous Thrombosis III: Interprofessional Care
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
01:11Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...